Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for prevention of contrast-associated acute kidney injury in coronary heart disease with CKD
ChiCTR2300074837Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of ulinastatin in Postcontrast Acute Kidney Injury (PC-AKI) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: serum creatinine, serum urea nitrogen and 4 more. Started Sep 2023; status: recruiting.
02
Drugs
ulinastatin
03
Conditions
Postcontrast Acute Kidney Injury (PC-AKI)
Beyond the preview
Go deeper on ChiCTR2300074837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074837.